Nuveen, LLC Arcus Biosciences, Inc. Transaction History
Nuveen, LLC
- $315 Billion
- Q1 2025
A detailed history of Nuveen, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Nuveen, LLC holds 131,859 shares of RCUS stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
131,859Holding current value
$1.18 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RCUS
# of Institutions
201Shares Held
53.4MCall Options Held
318KPut Options Held
168K-
Black Rock Inc. New York, NY9.76MShares$87.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.69MShares$59.8 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.52MShares$31.5 Million0.39% of portfolio
-
State Street Corp Boston, MA2.99MShares$26.8 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2MShares$17.8 Million0.07% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $645M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...